宫颈癌免疫治疗研究进展  

Research progress on cervical cancer immunotherapy

作　　者：张卉迎(综述) 王云飞(审校)[2] ZHANG Huiying;WANG Yunfei(School of Clinical Medicine,Jining Medical University,Jining 272013,China;Affiliated Hospital of Jining Medical University,Jining 272029,China)

机构地区：[1]济宁医学院临床医学院,济宁272013 [2]济宁医学院附属医院,济宁272029

出　　处：《济宁医学院学报》2024年第6期533-536,共4页Journal of Jining Medical University

摘　　要：在女性恶性肿瘤中,宫颈癌是一种较为典型的妇科肿瘤。宫颈癌在早期往往没有明显的症状和体征,而到了中晚期患者通常需要通过手术、放疗和化疗等方法进行治疗,但预后通常不佳。随着分子生物学及免疫学的迅速发展,人们对肿瘤发病机制有了更深入地了解,免疫治疗成为恶性肿瘤的治疗新方法,也成为宫颈癌治疗的研究热点。本文就简要综述宫颈癌免疫治疗的最新研究进展,包括就HPV疫苗、过继性T细胞疗法(TILs、TCR-T、CAR-T)、肿瘤免疫检查点抑制疗法(PD-1/PD-L1通路抑制剂、CTLA-4检查点抑制剂)及多种免疫治疗联合治疗宫颈癌的策略。Among women′s malignant tumors,cervical cancer is a more typical gynecological tumor.There are no obvious symptoms and signs of cervical cancer in the early stage.Patients in the middle and late stages are treated by surgery,radiotherapy and chemotherapy,and the prognosis is relatively poor.The rapid development of molecular biology and immunology has discovered the pathogenesis of tumors.Immunotherapy has become a new method of treating various malignant tumors and a research hotspot for cervical cancer treatment.This article summarizes the research progress of HPV vaccine,secondary T cell therapy(TILs,TCR-T,CAR-T),tumor immune checkpoint inhibition therapy(PD-1/PD-L1 pathway inhibitor,CTLA-4 checkpoint inhibitor)and multiple immunotherapy combined treatment of cervical cancer.

关 键 词：宫颈癌 免疫治疗 HPV疫苗 过继性T细胞疗法 肿瘤免疫检查点抑制疗法 联合治疗 

分 类 号：R737.33[医药卫生—肿瘤]